Antimicrobial Therapeutics MarketSize and Trends

The global antimicrobial therapeutics market size was valued at US$ 110.20 Bn in 2023 and is expected to reach US$ 161.77 Bn by 2030, grow at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2030.

The growth of the global antimicrobial therapeutics market is propelled by several factors. Firstly, the increasing prevalence of infectious diseases worldwide serves as a significant driver.

Secondly, the rise in multidrug-resistant (MDR) infections contributes to the expansion of the antimicrobial therapeutics market. MDR infections are caused by microorganisms that have developed resistance to one or more antimicrobial agents. The emergence of such infections poses a considerable challenge to the global healthcare system, necessitating the development of novel treatment options.

Lastly, the increasing for innovative antimicrobial agent’s drive the growth of the market over the forecast period. The current pipeline of antimicrobial agents is limited, highlighting the need for the discovery and development of new and effective treatment modalities to combat infectious diseases.

These factors collectively drive the expansion of the antimicrobial therapeutics market, addressing the urgent need for effective treatments against infectious diseases and multidrug-resistant infections.

On the product side, antiviral and antifungal drugs are anticipated to be the fastest growing segments. The rise in serious viral infections like HIV, hepatitis, influenza etc. necessitates newer antiviral therapies. Meanwhile, increasing incidence of opportunistic fungal infections associated with various diseases and medical conditions will bolster the need for antifungal medicines. Significant untapped demand also exists within developing Latin American and Middle Eastern countries for all categories of antimicrobial products.

Global Antimicrobial Therapeutics Market Trends:

Increasing adoption of inorganic growth strategies such as agreement: Increasing adoption of inorganic growth strategies, such as agreements by the key players in the market, is expected to drive the growth of the market over the forecast period. For instance, on March 30, 2023, GSK plc, a pharmaceutical company, and SCYNEXIS, Inc., a biotechnology company that develops products for the treatment of fungal infections, announced they had entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets), a U.S FDA-approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC). This exclusive license agreement gives GSK plc rights to commercialize Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.
Increasing acceptance of New Drug Application (NDA): Increasing acceptance of New Drug Application (NDA) is expected to drive the growth of the market over the forecast period. For instance, in December 2022, F2G Inc., a biotechnology company, announced that the U.S. FDA has accepted for filing of its New Drug Application (NDA) for olorofim for the treatment of invasive fungal infections in patients with limited or no treatment options.
High prevalence of bacterial tuberculosis, chlamydia, and bacterial vaginosi: Increasing prevalence of bacterial infections such as bacterial tuberculosis, chlamydia, bacterial vaginosi is expected to drive the growth of the market over the forecast period. For instance, according to the data of World Health Organization (WHO) in October 2021, a total of 1.5 Bn people died from Tuberculosis (TB) in 2020 (including 214 000 people with HIV). Worldwide, TB is the 13th leading cause of death and the second leading infectious disease after COVID-19 (above HIV/AIDS).
Facility Expansion: Increasing facility expansion by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, in June 2022, Pfizer Inc., a global pharmaceutical company, announced that it is further strengthening its U.S. manufacturing with a US$120 Bn investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, paxlovidtm tablets. Paxlovidtm is an antiviral drug.